Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYL-02 Gene Therapy in Locally Advanced Pancreatic Adenocarcinoma
NCT02806687Phase 2Completed
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Jan 2017
- Primary completion
- Jun 2022
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in pancreatic ductal adenocarcinoma (PDAC) comparing Gene Therapy product CYL-02 with Standard of care (2 arms). Primary endpoint: Progression-free survival at 12 months. Started Jan 2017; status: completed.
02
Drugs
CYL-02
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02806687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02806687.